The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with ...

Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...

Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now expects ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

The black diamonds that are found on tape measures have been a source of confusion for many - but it turns out that they ...

The strategic worldwide licensing agreement grants Servier the rights to develop and commercialize BDTX-4933, a therapy currently in Phase 1 development. Under the terms of the deal, Black Diamond ...

Black Diamond Equipment BD Vision harnesses are being recalled due to premature degradation of its construction and materials ...

Servier will be responsible for development and global commercialisation of the therapy for several indications.

Black Diamond Therapeutics Inc. is getting $70 million up front and could earn up to $710 million in milestone payments in a deal with Servier for phase I-stage BDTX-4933, a small-molecule candidate ...